ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors

ALK inhibitor crizotinib has shown potent antitumor activity in children with refractory Anaplastic Large Cell Lymphoma (ALCL) and the opportunity to include ALK inhibitors in first-line therapies is oncoming. However, recent studies suggest that crizotinib-resistance mutations may emerge in ALCL pa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Lovisa, Federica, Cozza, Giorgio, Cristiani, Andrea, Cuzzolin, Alberto, Albiero, Alessandro, Mussolin, Lara, Pillon, Marta, Moro, Stefano, Basso, Giuseppe, Rosolen, Angelo, Bonvini, Paolo
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2015
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4395299/
https://ncbi.nlm.nih.gov/pubmed/25874976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0121378
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items